Although many biomarkers, such as TP53 status and STK11 mutations, correlate with a poor prognosis in cervical cancer,10, 20 a prognosis‐based classification for cervical cancer patients undergoing chemoradiotherapy remains to be established. This evidence concerns the gene STK11 and cervical carcinoma.